AIM
ATRS

Acrospire Investment Management’s Antares Pharma, Inc. ATRS Stock Holding History

Acrospire Investment Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,250
Closed -$17K – 1665
2017
Q2 		$17K Sell
5,250
-21,066
-80% -$59.7K 0.02% 1626
2017
Q1 		$75K Sell
26,316
-16,517
-39% -$39.7K 0.06% 552
2016
Q4 		$100K Buy
+42,833
New +$81.6K 0.04% 927

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acrospire Investment Management's ATRS Position: Q3 2017 in Review

Acrospire Investment Management sold out of Antares Pharma, Inc. (ATRS) in Q3 2017, closing a stake of 5,250 shares — an estimated $17K sold.

Acrospire Investment Management first reported a position in ATRS in Q4 2016 and held it in 3 quarters. The position peaked at $100K in Q4 2016. 103 funds tracked by Wall St. Rank hold ATRS as of Q3 2017.

  • Acrospire Investment Management reported no remaining Antares Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 5,250 Antares Pharma, Inc. shares in Q3 2017, an estimated $17K.
  • Acrospire Investment Management first reported a position in Antares Pharma, Inc. in Q4 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Antares Pharma, Inc. position peaked at $100K in Q4 2016.
  • 103 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.